Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation

Pharmacogenomics (PGx) offers patients personalized treatment by guiding medication selection and dosing based on their genetic profiles. However, widespread clinical implementation remains limited, in part due to patient and provider concerns about cost and willingness to pay (WTP). This study evaluated whether an outpatient clinical consultation that educates patients on their PGx results influences their WTP for PGx testing. As part of the PROTECT-Rx trial at the University of Chicago, high-risk patients received free PGx testing and a virtual consultation at the Personalized Therapeutics Clinic (PTC). Patients completed pre- and post-visit surveys assessing PGx knowledge and WTP. Of 129 patients who had completed a PTC visit as of 1/2025, 76 completed both the PTC visit and surveys. WTP for PGx testing increased significantly from 68% pre-visit to 83% post-visit (p = 0.029). After controlling for social vulnerability, patients who had at least one cautionary or high-risk PGx result were nearly 3 times more likely to report higher willingness-to-pay (OR 2.76, p = 0.037). A single PGx consultation with review of personal results significantly increases patients' WTP for testing, particularly among those with actionable PGx results. Understanding individual risk and the relevance of PGx enhances perceived value, suggesting that patient education is an important component in the broader adoption of pharmacogenomic testing.